ReproSource
Private Company
Funding information not available
Overview
ReproSource is a private, commercial-stage diagnostics company serving the reproductive medicine market. It has established itself as a trusted leader by developing and offering specialized, high-complexity tests for female fertility assessment (e.g., AMH, Ovarian Assessment Report), male fertility (comprehensive semen analysis, sperm DNA fragmentation), and recurrent pregnancy loss. The company operates a dual business model, catering both to clinical diagnostics for patient care and laboratory services for clinical research organizations, leveraging its expertise to ensure test accuracy and superior client service. Its strategic position within the larger Quest Diagnostics network provides scale and billing infrastructure while allowing it to maintain a focused brand on reproductive health.
Technology Platform
Specialized clinical laboratory platform offering proprietary and advanced diagnostic assays for reproductive health, including the Ovarian Assessment Report (OAR), refined AMH testing, at-home semen analysis collection, sperm DNA fragmentation, oxidative stress tests, and comprehensive panels for recurrent pregnancy loss.
Opportunities
Risk Factors
Competitive Landscape
ReproSource competes in the reproductive diagnostics niche against large national clinical laboratories (e.g., LabCorp, Quest's core business), other specialized fertility labs (e.g., RMA Labs, various academic medical center labs), and emerging digital health/wellness companies offering direct-to-consumer tests. Its differentiation is its exclusive focus, advanced test menu (like OAR), strong research credentials, and high-touch client service, all backed by the infrastructure of Quest Diagnostics.